Body awareness therapy: A new strategy for relief of symptoms in irritable bowel syndrome patients

Table 3 Gastrointestinal symptom score for 21 apparently healthy controls and for 21 IBS patients at 0, 12 and 24 wk of treatment and 6 mo after end of treatment

Category	Before treatment		After 12 wk		After 24 wk		6 mo after end of treatment
	M	Md (IQR)	M	Md (IQR)	M	Md (IQR)	M	Md (IQR)
AHC group
Totally	0.4	0 (1)d
Pain	0.4	0 (1)d
Flatulence	0.4	0 (1)d
Nausea	0.2	0 (1)
Constipation	0.6	0 (1)b
Diarrhoea	0.3	0 (1)d
Motility	0.5	0 (1)d
Other	0.3	1 (0)d
IBS patients
Totally	1.8	1 (3)	1.6	1 (3)d	1.3	1 (2)d	1.4	1 (2)d
Pain	1.9	2 (2)	1.9	2 (3)	1.5	2 (2)d	1.4	1 (2)d
Flatulence	2.5	2 (3)	2.2	2 (2)b	1.8	2 (2)d	2.0	2 (2)b
Nausea	1.4	1 (2)	1.0	0 (2)a	0.9	0 (2)a	0.8	0 (1)a
Constipation	1.9	2 (3)	1.5	1 (2)a	1.1	1 (2)b	1.4	1 (2)a
Diarrhoea	1.9	1 (3)	1.6	2 (1)	1.2	1 (2)d	1.2	1 (2)b
Motility	2.6	2 (3)	2.2	2 (2)a	1.9	2 (1)a	2.1	2 (2)
Others	1.2	1 (1)	1.2	1 (1)	1.1	1 (1)a	1.1	0 (1)a

The result is shown totally and categorized. The higher score the more symptoms. M denotes mean, MD: median; IQR: inter quartile range; AHC: apparently healthy controls.

^aP < 0.05,

^bP < 0.01,

^dP < 0.001 vs IBS patients at 0 wk.